Autoimmune and Autonomous Toxic Goiter: Differentation and Clinical Outcome After Drug Treatment

  • H. Schleusener
  • G. Holl
  • J. Schwander
  • K. Badenhoop
  • J. Hensen
  • R. Finke
  • G. Schernthaner
  • W. R. Mayr
  • P. Kotulla
  • R. Holle

Abstract

Our own data presented in this paper are taken from investigations of a multi center prospective study*, in which the following colleagues participate: Althoff (Frankfurt), Badenhoop (Mannheim), Benker (Essen), Beyer (Mainz), Bd’rner (Wiirzburg), Bogner (Berlin), Bretzel (GieBen), Fiek (Berlin), Finke (Berlin), GrSf (Berlin), Grebe (GieBen), Ifengst (Miinster), Hensen (Berlin), Holl (Berlin), Hopf (Berlin), Hufner (Heidelberg), Joseph (Marburg), Jungmann (Frankfurt), Kahaly (Mainz), Kotulla (Berlin), Koppenhagen (Berlin), Mtiller-Eckardt (GieBen), Pickardt (Miinchen), Raue (Heidelberg), Reiners (WCirzburg), Reinwein (Essen), Schatz (GieBen), Schleusener (Berlin), Schoffling (Frankfurt), Schumm (Frankfurt), Schwander (Berlin), Schwedes (Mannheim), Seif (TUbingen), Usadel (Mannheim), WLtte (Miinchen), Ziegler (Heidelberg)

Keywords

Europe Tyrosine Iodine Adenoma Perchlorate 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Alexander, W.D., McLarty, D.G., Robertson, J., Shimmins, J., Brownlie, B.E.W., Harden, R.M., and Patel, A.R., 1970, Prediction of the long-term results of antithyroid drug therapy for thyrotoxicosis, J. Clin. Endocr., 30: 540.PubMedCrossRefGoogle Scholar
  2. Benker, G., Reinwein, D., Grobe, R., Creutzig, H., and Hirche, H., 1986, Effects of high and lew dose of methimazole in patients with Graves’ thyrotoxicosis, International Symposium “Advances in Thyroidology, Lübeck 1986, Acta Endocrinol, in press.Google Scholar
  3. Boukis, M.A., Koutras, D.A., Souvatzoglu, A., Evangelopoulou, A., Vrontakis, M., Karaiskos, K.S., Piperingos, G.D., Kitsopanidis J., and Moulopoulos, S.D., 1985, Iodine-induced autoimmunity, in: “Thyroid Disorders Associated With Iodine Deficiency And Excess”, Serono Symposium, R. Hall, J. Kobberling, eds., Raven Press, New York, p. 217.Google Scholar
  4. Burman, K.D., Baker, and J.R., Jr.,1985, Immune mechanisms in Graves* disease, Endocr. Rev., 6: 183.PubMedCrossRefGoogle Scholar
  5. Cassidy, C.E., 1970, Thyroid suppression test as index of outcome of hyperthyroidism treated with antithyroid drugs, Metab., 19: 745.CrossRefGoogle Scholar
  6. Dahlberg, P.A., Karlsson, F.A., Jans son, R., and Wide L., 1985, Thyrotropin-releasing hormone testing during antithyroid drug treatment of Graves* disease as an inidcator of remission, J. Clin. Endocr. Metab., 61: 1100.PubMedCrossRefGoogle Scholar
  7. Dralle, H., Backer, W, Dbhler, K.D., SchrSder, S., Haindl, H., Geerlings, H., Schwarzrock, R., and Pichlmayr, R., 1985, Growth and function of thirty-four human benign and malignant thyroid xenografts in untreated nude mice, J. Clin. Endocrinol. Metab., 59: 175.Google Scholar
  8. Greer, M.A., Kammer, H., and Bouma, D.J., 1977, Short-term antithyroid drug therapy for the thyrotoxicosis of Graves’ disease, New Engl. J. Med., 297: 173.PubMedCrossRefGoogle Scholar
  9. Hackenberg, K., Reinwein, D., Schemmel, K.,1973, RezidivhSufigkeit methimazolbehandelter Hyperthyreosen und Suppressibilitat der Schilddrtise, Münch. med. Wschr., 115: 2216.Google Scholar
  10. Hennemann, G., Krenning, E.P., and Sankaranarayanan, K., 1986, Place of radioactive iodine in treatment of thyrotoxicosis, lancet I:1369.CrossRefGoogle Scholar
  11. Hensen, J., Kotulla, P., Finke, R., Badenhoop, K., Koppenhagen, K., Meinhold, H., and Schleusener, H., 1984, 10 years experience with consecutive measurement of thyrotropin binding inhibiting antibodies (TBIAB), J. Endocrinol. Inves., 7: 215.Google Scholar
  12. Herrmann, J., Emrich, D., Kemper, F., Kobberling, J., Pickardt, R.C., and Stubbe, P., 1984, JodexzeB und seine Auswirkung, Dtsch. Med. Wschr., 109: 1077.PubMedGoogle Scholar
  13. Hirota, Y., Tamai, H., Hayashi, Y., Matsubayashi, S., Matsuzuka, F., Kiima, K., Kumagai, L.F., and Nagataki, S., 1986, Thyroid function and histology in fourty-five patients with hyperthyroid Graves’ disease in clinical remission more than ten years after thionamide drug treatment, J. Clin. Endocrinol. Metab., 62: 165.PubMedCrossRefGoogle Scholar
  14. Jans son, R., Dahlberg, P.A., Johansson, H., and LindstrcJm, B., 1983, Intrathyroidal concentrations of methimazol in patients with Graves’ disease, J. Clin. Endocrinol. Metabol., 57: 129.CrossRefGoogle Scholar
  15. Laurberg, P., Hansen, P.E.B., Iversen, E., Jensen, S.E., and Weeke, J., 1986, Goitre size and outcome of medical treatment of Graves’ disease, Acta Endocrinol., III: 39.Google Scholar
  16. Lazarus, J.H., Burr, M.L., McGregor, A.M., Weetman, A.P., Ludgate, M., Woodhead, J.S., and Hall, R., 1984, The prevalence and progression of autoimmune thyroid disease in elderly, Acta Endocrinol., 106: 199–202.PubMedGoogle Scholar
  17. Leclére, J., Bene, M.C., Duprez, A., Fuare, G., Thomas, J.L., Yignaud, J.M., and Burlet, C., 1984, Behaviour of thyroid tissue from patients with Graves’ disease in nude mice, J. Clin. Endocrinol. Metab., 59: 175.PubMedCrossRefGoogle Scholar
  18. McGregor, A.M., Petersen, M.M., McLachlan, S.M., Rooke, P., Sknith, B.R., and Hall, R., 1980, Carbimazole and the autoimmune response in Graves’ disease, New Engl. J. Med., 303: 302.PubMedCrossRefGoogle Scholar
  19. McGregor, A.M., Weetman, A.P., Ratanachaiyavong, S., Owen, G.M., Ibbertson, H.K., and Hall, R., 1985, Iodine: an influence on the development of autoimmune thyroid disease?, in: “Thyroid Disorders Associated With Iodine Deficiency And Excess”, Serono Symposium, R., Hall, J. KSbberling, eds., Raven Press, New York, p. 209.Google Scholar
  20. McKenzie, J.M., 1980, Thyroid-stimulating antibody in Graves’ disease, in: “Thyroid Today,” J.H. Oppenheimer, ed., 3 (5), 1.Google Scholar
  21. Müller-Gärtner, H-W., Schneider, C., and Schröder, S., 1986, Autoimmune-resistance in Graves’ disease tissues: indication of a structural and functional heterogenicity, Acta Ehdocrinol., 113: 233.Google Scholar
  22. Meng, W., Meng, S., Stöwhas, H., Männchen, E., Ventz, M., and Hampel, R., 1982, Ergebnisse der thyreostatischen Langzeittherapie der Hyperthyreose - EinfluB der Struma, der Orbitopathie und der Behandlungsdauer, Dt. Gesundh.-Wesen, 37: 1956.Google Scholar
  23. Meng, W., Stöwhas, H., Männchen, E., Weber, A., Ventz, M., Ifempel, R., Meng, S., and Jäger, B., 1983, Prospektive Studie zur Frage der Erkennung einer Remission und zur EinschStzung der Prognose bei thyreostatisch behandelter Hyperthyreose. Dt. Gesund-Wesen, 38: 365.Google Scholar
  24. Peter, H.J., Gerber, H., Studer, H., and Smeds, S., 1985, Pathogenesis of heterogeneity in human multinodular goiter, J. Clin. Invest., 76: 1982.CrossRefGoogle Scholar
  25. Pfannenstiel, P., 1983, Heutiger Stellenwert und Jhdikationen der Sonographic der Schilddriise, Akt. Endokr. Stoffw., 4: 142–150.Google Scholar
  26. Romaldini, J.H., Bromberg, N., Werner, R.S., Tanaka, L.M., Rodrigues, H.F., Werner, M.C., Farah, C.S., and Reis, L.C.F., 1983, Comparison of effects of higih and low dosage regimens of antithyroid drugs in the management of Graves’ hyperthyroidism, J. Clin. Endocrinol. Metab., 57: 563.PubMedCrossRefGoogle Scholar
  27. Schicha, H., Emrich, D., Schreivogel, I., 1985, Hyperthyroidism due to Graves’ disease and due to autonomous goiter, J. Endocrinol. Invest., 8: 399–407.PubMedGoogle Scholar
  28. Schleusener, H., Schwander, J., Ho11, G., Badenhoop, K., Hensen, J., Finke, R., Schernthaner, G., Mayr, W.R., and Kotulla, P.,1986, Do HIA-DR-typing and measurement of TSH-receptor antibodies help in the prediction of the clinical course of Graves’ thyrotoxicosis after antithyroid drug treatment?, International Symposium “Advances in Thyroidology, Lübeck 1986, Acta Endocrinol., in press.Google Scholar
  29. Slingerland, D.W., Barrows, B.A., 1979, Long-term antithyroid treatment in hyperthyroidism, JAMA, 242: 2408.PubMedCrossRefGoogle Scholar
  30. Studer, H., Peter, H.J., and Gerber, H., 1985a, Toxic nodular goiter, Clinics Endocrinol. Metabol., 14: 351.Google Scholar
  31. Studer, H., Peter, H.J., and Gerber, H., 1985b, Morphologic and functional changes in developing goiters, in: “Thyroid Disorders Associated With Iodine Deficiency And Excess,” R. Hall, J.. Kobberlin, eds., Raven Press, Hew York, p. 227.Google Scholar
  32. Studer, H.,1985c, Growth control and follicular cell neoplasia, in: “New Frontiers In Thyroidology,” G.A. Medeiros-Neto, E. Gaitan, eds., Proceedings of the 9th International, Thyroid Congress Sao Paulo, Brazil, Plenum Press, New York.Google Scholar
  33. Tamai, H., Nakagawa, T., Fukino, O., Ohsako, N., Shinzato, R., Suematsu, H, Kuma, K., Matsuzuka, F., and Nagataki, S.,1980, Thionamide therapy in Graves’ disease: Relation of relapse rate to duration of therapy, Ann. Int. Med., 92: 488.PubMedGoogle Scholar
  34. Wartofsky, L., 1973, Low remission after therapy for Graves’ disease, JAMA, 226: 1083.PubMedCrossRefGoogle Scholar
  35. Weetman, A.P., McGregor, A.M., and Hall, R., 1984, Evidence for an effect of antithyroid drugs on the natural history of Graves’ disease, Clin. Endocrinol., 21: 163.CrossRefGoogle Scholar
  36. Wenzel, K.W., and Lente, J.R., 1984, Similar effects of thionamide drugs and perchlorate on thyroid-stimulating immunoglobulins in Graves’ disease: Evidence against an immunosuppressive action of thionamide drugs, J. Clin. Endocrinol. Metab., 58: 62.PubMedCrossRefGoogle Scholar
  37. Wick, G., Most, J., Schauenstein, K., Krömer, G., Dietrich, H., Ziermiecki, A., Fassler, R., Schwarz, S., Neu, N., and Hala, K., 1985, Spontaneous autoimmune thyroiditis - a bird’s eye vLew, Immunology Today, 6: 359–364.CrossRefGoogle Scholar
  38. Yamada, T., Koizumi, Y., Sato, A., Hashizume, K., Aizawa, T., Takasu, N., and Nagata, H., 1984, Reappraisal of the 3,5,3’-triiodothyroninesuppression test in the prediction of long term outcome of antithyroid drug therapy in patients with hyperthyroid Graves’ disease, J. Clin. Endocrinol. Metab., 58: 676.PubMedCrossRefGoogle Scholar
  39. Yamamoto, M., Totsuka, Y., Kojima, J., Yamashita, N, Togawa, K., Sawakii, N., and Ogata, E., 1983, Outcome of patients with Graves’ disease after long-term medical treatment guided by triiodothyronine (T3) suppression test, Clin. Endocr., 19: 467.PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1987

Authors and Affiliations

  • H. Schleusener
    • 1
  • G. Holl
    • 1
  • J. Schwander
    • 1
  • K. Badenhoop
    • 1
  • J. Hensen
    • 1
  • R. Finke
    • 1
  • G. Schernthaner
    • 2
  • W. R. Mayr
    • 3
  • P. Kotulla
    • 1
  • R. Holle
    • 4
  1. 1.Endocr. Dept., Medical Clinic, Klinikum SteglitzFreie Universität BerlinBerlinGermany
  2. 2.IInd Medical Clinic and Institute of Blood Group SerologyUniversity of ViennaViennaAustria
  3. 3.University of ViennaViennaAustria
  4. 4.Center for Methodical Guidance of Therapeutic StudiesUniversity of HeidelbergHeidelbergGermany

Personalised recommendations